RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 363.37K | $34.60M | n/a | −1 |
| Q2 2026 | 113 | +6 | 44.38M | $4.90B | +14 | −7 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | n/a |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | n/a | n/a |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | n/a |
| Q2 2024 | 8 | n/a | 9.56M | $392.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 363.37K | -2.6% | $34.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Wealth Enhancement Advisory… | $204,334 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 284 holders, 72.02M shares, $6.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.82K sh · $189,965
Officer, Director · 8.70K sh · $899,634
Officer, Director · 30.75K sh · $3.15M
Officer, Director · 6.44K sh · $655,145
Officer, Director · 2.30K sh · $241,937
Officer · 11.51K sh · $1.21M
Officer · 23.07K sh · $2.41M
Officer · 28.19K sh · $2.99M
Officer · 2.01K sh · $233,031
Officer · 1.56K sh · $182,170
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology